Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H32N2O2.2ClH |
| Molecular Weight | 393.391 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1
InChI
InChIKey=ZHRVNCCPAKIGRH-UHFFFAOYSA-N
InChI=1S/C19H32N2O2.2ClH/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4;;/h7-11,16,18,20H,5-6,12-15H2,1-4H3;2*1H
| Molecular Formula | C19H32N2O2 |
| Molecular Weight | 320.4696 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419
Curator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419
Camylofin is an antimuscarinic. This medication is used as antispasmodic in biliary colic, renal and ureteric colic, dysmenorrhoea, peptic ulcer and chronic enterocolitis. It is used to treat stomach ache in infants and children. Camylofin should be the first choice and may be preferred over other drugs for cervical dilatation and acceleration of active phase of labor.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14831430
Curator's Comment: refernce retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13331655
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D07076 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ANAFORTAN Approved UseCamylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity. |
|||
| Primary | ANAFORTAN Approved UseCamylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Skin rash, Tachycardia... Other AEs: Skin rash (18.8%) Sources: Tachycardia (12.5%) Drowsiness (6.25%) Facial flushing (6.25%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Tachycardia | 12.5% | 120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Skin rash | 18.8% | 120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Drowsiness | 6.25% | 120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Facial flushing | 6.25% | 120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antispasmodics for labour. | 2012-08-15 |
|
| Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. | 2010-09 |
|
| Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. | 2007-03-22 |
|
| A study of metabolism of isoamyl alpha-[N-(beta-diethylamino-ethyl)]-aminophenylacetate (avacan). | 1956-03 |
|
| [Pharmacology of Avacan]. | 1951-04-06 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:47 GMT 2025
by
admin
on
Mon Mar 31 17:59:47 GMT 2025
|
| Record UNII |
MO02H82C7M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C004644
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
227-571-0
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
236175
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | RxNorm | ||
|
759249
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
22182
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
5892-41-1
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
CHEMBL253592
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
m99
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID70974421
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
100000084848
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
SUB01018MIG
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY | |||
|
MO02H82C7M
Created by
admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |